Clinical Trial Update: A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients [Phase 2]

View source ↗

Summary

A multicenter phase 2 study is assessing the feasibility of using 5-ALA in pediatric brain tumor patients; the trial is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor

Drugs mentioned

• 5-aminolevulinic acid (5-ALA) (5-aminolevulinic acid)

Snippet

Sponsor: Costas Hadjipanayis | Conditions: Pediatric Brain Tumor | Phase 2 | Status: NOT_YET_RECRUITING